BioNTech and Bristol Myers Squibb report phase 2 pumitamig data after immunotherapy-chemo progression in advanced NSCLC
BNTX•BioNTech and Bristol Myers Squibb reported encouraging global phase 2 data for pumitamig in advanced NSCLC after progression on immunotherapy plus chemotherapy.
1. Phase 2 data
BioNTech and Bristol Myers Squibb reported encouraging global phase 2 data for pumitamig in advanced NSCLC after progression on immunotherapy plus chemotherapy.
